Endo Tools Therapeutics

The company's core business revolves around developing and manufacturing advanced, incisionless, and minimally invasive medical devices for use with standard endoscopes. ETT targets procedures that are difficult to perform with standard gastroscopes, such as endoscopic suturing and tissue approximation. Its main product is the endomina® system, a platform that provides triangulation capabilities for surgical endoscopy. The system consists of a triangulation platform that can be attached to a standard endoscope and an instrument for tissue piercing and approximation (TAPES). This technology gives the endoscopist a flexible, independently movable therapeutic channel, enabling a two-handed, laparoscopic-like approach through a natural orifice like the mouth. The endomina® system is designed for procedures like bariatric interventions, treating Gastroesophageal Reflux Disease (GERD), and Endoscopic Full Thickness Resection (EFTR).

The endomina® system received its CE mark in Europe, where over 500 procedures have been performed, and gained FDA 510(k) clearance in the U.S. in early 2022. The company initiated its U.S. commercial launch in the first half of 2022. ETT's business model focuses on selling these devices to hospitals and clinics, serving interventional gastroenterologists. The company also emphasizes professional training to ensure proficiency with its system. To date, Endo Tools Therapeutics has raised a total of $18.7 million over three funding rounds, with its latest Series D round in January 2021 raising $9.66 million, led by White Fund.